Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Iterum Therapeutics plc Director's Dealing 2018

Nov 1, 2018

34796_dirs_2018-11-01_3e823d52-f108-441f-88e5-f2a73fe17be5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Iterum Therapeutics plc (ITRM)
CIK: 0001659323
Period of Report: 2018-10-30

Reporting Person: Chin Mark (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-10-30 Ordinary Shares P 58000 $6.10 Acquired 1089903 Indirect

Footnotes

F1: The Reporting Person is an Investment Director for Arix Bioscience Holdings Ltd.